CNS制药公司得到Nasdaq公司延期至2025年3月,以满足最低投标价格要求。 CNS Pharmaceuticals receives Nasdaq extension until March 2025 to meet minimum bid price requirement.

CNS制药公司是一家以脑和中枢神经系统癌症治疗为重点的生物制药公司,已获得从Nasdaq延长到2025年3月11日的延期,以达到最低投标价格要求。 CNS Pharmaceuticals, a biopharmaceutical firm focused on cancer treatments for the brain and central nervous system, has received an extension from Nasdaq until March 11, 2025, to comply with its minimum bid price requirement. 这是该公司的首例例外,该公司正在开发Berubicin,这是对血浆瘤等疾病的一种潜在的新治疗方法。 This is the first such exception for the company, which is developing Berubicin, a potential new treatment for conditions like glioblastoma. 该延长使CNS制药公司能够集中精力推进其癌症药物管道。 The extension allows CNS Pharmaceuticals to concentrate on advancing its cancer drug pipeline.